| HOME >> BIOLOGY >> TECHNOLOGY |
SOMERSET, N.J., Oct. 5 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced that it will host a conference call and Webcast at 11 a.m. EDT on Monday, Oct. 15. During the call, Kuslima Shogen, Alfacell's chairman and chief executive officer, and Lawrence A. Kenyon, executive vice president, chief financial officer and corporate secretary, will present an overview of Alfacell's financial performance for the fiscal fourth quarter and year ended July 31, 2007.
To participate in the live conference call, U.S. residents may dial 1-877-407-9205, and international callers may dial 1-201-689-8054. A replay of the call will be available until Oct. 22. To access the replay, U.S. residents may dial 1-877-660-6853, and international callers may dial 1-201-612-7415 and enter account number 286 and conference ID number 257455. A live Webcast and replay of the conference call will be available on Alfacell's Web site at http://www.alfacell.com.
About Alfacell Corporation
Alfacell Corporation is the first company to advance a
biopharmaceutical product candidate that works in a manner similar to RNA
interference (RNAi) through late-stage clinical trials. The product
candidate, ONCONASE(R), is an RNase that overcomes the challenges of
targeting RNA for therapeutic purposes while enabling the development of a
new class of targeted therapies for cancer and other life-threatening
diseases. In addition to an ongoing Phase IIIb study in malignant
mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in
non-small cell lung cancer (NSCLC) and other solid tumors. For more
information, visit
'/>"/>
| SOURCE Alfacell Corporation Copyright©2007 PR Newswire. All rights reserved |